Monte Rosa Therapeutics, Inc.
GLUE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $224 | $128 | $55 | $346 |
| Short-Term Investments | $148 | $104 | $208 | $0 |
| Receivables | $0 | $1 | $8 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $3 | $5 | $3 |
| Total Curr. Assets | $377 | $236 | $276 | $349 |
| Property Plant & Equip (Net) | $56 | $63 | $62 | $12 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $5 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $5 | $5 | $5 | $0 |
| Total NC Assets | $61 | $68 | $67 | $18 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $439 | $304 | $342 | $366 |
| Liabilities | – | – | – | – |
| Payables | $17 | $11 | $8 | $7 |
| Short-Term Debt | $4 | $3 | $3 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $117 | $18 | $0 | $0 |
| Other Curr. Liab. | $19 | $15 | $15 | $10 |
| Total Curr. Liab. | $157 | $47 | $26 | $17 |
| LT Debt | $39 | $43 | $44 | $0 |
| Deferred Rev, NC | $16 | $32 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $4 | $3 | $2 | $2 |
| Total NC Liab. | $59 | $78 | $45 | $2 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $43 | $46 | $47 | $0 |
| Total Liabilities | $216 | $125 | $71 | $19 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$439 | -$366 | -$231 | -$122 |
| AOCI | -$3 | -$3 | -$2 | -$2 |
| Other Equity | $665 | $548 | $504 | $472 |
| Total Equity | $223 | $179 | $271 | $348 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $439 | $304 | $342 | $366 |
| Net Debt | -$182 | -$82 | -$8 | -$346 |